Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotechnology Surging
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Articles about Puma Biotechnology
